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ABSTRACT
Background. Sentinel lymph node biopsy (SLNB) has
become standard of care as a staging procedure in patients
with invasive breast cancer. A positive SLNB allows
completion axillary lymph node dissection (cALND) to be
performed. The axillary recurrence rate (ARR) after cAL-
ND in patients with positive SLNB is low. Recently,
several studies have reported a similar low ARR when
cALND is not performed. This review aims to determine
the ARR when cALND is omitted in SLNB-positive
patients.
Methods. A literature search was performed in the Pub-
Med database with the search terms ‘‘breast cancer,’’
‘‘sentinel lymph node biopsy,’’ ‘‘axillary’’ and ‘‘recur-
rence.’’ Articles with data regarding follow-up of patients
with SLNB-positive breast cancer were identified. To be
eligible, patients should not have received cALND and
ARR should be reported.
Results. Thirty articles were analyzed. This resulted in
7,151 patients with SLNB-positive breast cancer in whom a
cALND was omitted (median follow-up of 45 months,
range 1–142 months). Overall, 41 patients developed an
axillary recurrence. 27 studies described 3,468 patients
with micrometastases in the SLNB, of whom 10 (0.3 %)
developed an axillary recurrence. ARR varied between 0
and 3.7 %. Sixteen studies described 3,268 patients with
macrometastases, 24 (0.7 %) axillary recurrences were
seen. ARR varied between 0 and 7.1 %. Details regarding
type of surgery and adjuvant treatment were lacking in the
majority of studies.
Conclusions. ARR appears to be low in SLNB-positive
patients even when a cALND is not performed. With-
holding cALND may be safe in breast cancer selected
patients such as those with isolated tumor cells or micro-
metastatic disease.
Since the 1990s, the sentinel lymph node biopsy (SLNB)
has become the standard staging procedure for patients
with invasive breast cancer.1 According to the current
treatment guidelines, treatment of the axilla in case of a
negative SLNB can be safely omitted.2 A positive SLNB
indicates that completion axillary lymph node dissection
(cALND) has to be performed.3 In case of four or more
positive lymph nodes in the dissection specimen, adjuvant
radiotherapy of the supra- and infraclavicular lymph nodes
is indicated.4 Axillary radiotherapy is possibly an appro-
priate alternative for cALND. In the AMAROS trial
cALND and axillary radiotherapy were compared; the
main objective was to show equivalent locoregional control
and reduced morbidity after radiotherapy. The final results
of this trial have not yet been established.5,6 Although a
cALND not only provides additional prognostic informa-
tion, it could also optimize regional control and potentially
improve overall survival.3 However, in 15–20 % of the
cases, a cALND leads to long-term complications such as
pain, paresthesia due to intercostobrachial nerve injury,
impairment of the shoulder function, or lymphedema.7,8
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The axillary recurrence rate (ARR) after a cALND has
been performed in patients with a positive SLNB is low.
Recent publications show rates that vary between 0.2 and
0.9 % for micrometastatic disease of the sentinel lymph
node (SLN) and around 1.0 % in case of macrometastatic
disease.9–11 These results are comparable with results from
older studies in which all patients had been treated with
ALNDs.12 Patients with positive axillary lymph nodes are
usually treated with adjuvant systemic therapy: hormone
therapy, chemotherapy or both. Although this might be an
important factor for the low recurrence rate in the axilla, in
case of breast conservative treatment radiotherapy itself on
the breast is considered an important reason for a low ARR.
Recently, several studies in patients with a positive
SLNB who predominantly underwent breast conservative
treatment have reported a low ARR when cALND had not
been performed.13–16 A prospective randomized trial
(ACOSOG Z0011) tried to investigate whether cALND
could safely be omitted in these patients. The trial was
closed early as a result of slow accrual. The slow accrual
probably implies that in daily practice there is still concern
about the safety of omitting a cALND. Because interest is
growing in omitting a cALND even if the SLNB is posi-
tive, this systematic review article aims to determine the




A literature search was performed in the PubMed data-
base using the search terms ‘‘breast cancer,’’ ‘‘sentinel
lymph node biopsy,’’ ‘‘axillary’’ and ‘‘recurrence.’’ Only
articles published in the past ten years and in the English
language were considered. References from the selected
articles were used to complete the search. Two reviewers
(C.F. and P.D.) independently performed the search;
potentially relevant articles were selected on the basis of
the title and abstract.
Review Inclusion and Exclusion Criteria
Articles with data regarding the follow-up of in cohorts
a prospectively or retrospectively analyzed cohort of
patients with SLNB-positive breast cancer, regardless of
whether it was a prospective cohort or one formed retro-
spectively were identified. Only articles were examined
that reported a cohort of patients with SLNB-positive
breast carcinoma confirmed by SLNB and had follow-up
data. The status of the positive SLNB was classified into
three categories: micrometastatic lymph node (B2.0 mm),
macrometastatic lymph node ([2.0 mm) and not specified.
Distinction between isolated tumor cells (ITC;\0.02 mm)
and micrometastatic disease (0.02–2.0 mm) was not pre-
sented in all articles and these were therefore combined as
micrometastatic (B2.0 mm). Only SLNB-positive patients
without a cALND were included. Cases in which it was
uncertain whether cALND had been performed were
excluded. Failure to report on the ARR also resulted in
exclusion from this review.
Adjuvant treatment (radiation, chemotherapy or hor-
mone therapy) was not subject to review. Therefore, failure
to report on the percentage of patients receiving adjuvant
treatment did not result in exclusion from this study. An
effort was made, however, to extract data on adjuvant
treatment when documented. Two studies reported 100 %
of the observed patients had received axillary radiotherapy
and were excluded. Additional information on age, clinical
T stage, lymphovascular invasion and type of surgery was
also collected.
Each article was reviewed independently by the two
reviewers (C.F. and P.D.), and discrepancies were resolved
by consensus.
Identification of Axillary Recurrence
Axillary recurrence was defined as the detection of
metastatic disease in the axilla based on a positive SLNB.
Patients with concurrent breast relapse who had developed
axillary disease based on a positive SLNB were not con-
sidered as having an axillary recurrence. In these instances,
the axillary recurrence could reflect insufficient local
control of the primary tumor. Additionally, some articles
only mentioned local or locoregional recurrence. The latter
were classified as having an axillary recurrence.
Statistical Analysis
Patient and tumor related characteristics and ARRs were
calculated by descriptive statistics.
RESULTS
A total of 216 articles were found in the PubMed
database; after an intensive review of the analysis reported
in the abstract, only 35 remained. The two articles report-
ing axillary radiotherapy in 100 % of the patients were
excluded.17,18 Three research groups reported results from
the same cohort in two or three different articles with a
progressively longer follow-up or an increased group size.
The articles with data reporting the longest follow-up were
included.19–21 Therefore, 30 articles were eligible for
analysis in this review.9,10,14–16,19–43
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Description of Study Data
In 30 articles results were presented for a total of 7,151
patients with SLNB-positive breast cancer in which a
cALND had not been performed. Median follow-up was
45 months (range 1–142 months). One study reported an
underpowered multicenter randomized clinical trial.9 Two
studies reported results from a nationwide database.10,22
All the other series were single center reports.9,10,14–16,19–43
A cALND was not performed because of patient or clinician
preference.14–16,21,24,35,37–40,42 Some studies retrospectively
analyzed patients with postoperative confirmed positive SLNs,
in which no secondary surgery had been performed on the
axilla.19,25,27,36,41,43 In total, 41 patients developed an axillary
recurrence without evidence of ipsilateral breast cancer recur-
rence. The ARR varied between 0 and 7.1 % in the different
studies.
ARR After Micrometastases/ITCs are Found
in the Sentinel Node
We further classified patients on the basis of the sentinel
node status. In a total of 27 studies 3,468 patients were
identified with micrometastatic disease in the sentinel node
who had not undergone a cALND (Table 1). Median fol-
low-up was 42 months; 10 patients (0.3 %) developed an
axillary recurrence. The axillary recurrences were reported
to occur in 3 patients who underwent breast-conserving
therapy (BCT) and in 2 patients who underwent mastec-
tomy. In 5 patients an axillary recurrence was reported, but
details regarding the type of breast surgery was not men-
tioned in the article. Of the 10 patients, two were treated
with adjuvant radiotherapy and one without. In the other
patients, only percentages of radiotherapy in the total group
of patients were given (21 % up to 72 %) or radiotherapy
was not mentioned at all.9,10,22–24,33,35
Two of the 27 studies investigated national databases.
From the Surveillance, Epidemiology, and End Results
database, Yi et al.22 identified 26,986 patients with disease-
positive lymph nodes, of which 4,425 (16.4 %) had only
undergone SLNB. After nodal evaluation with lymph node
count threshold, i.e. patients were considered only to have
undergone a SLNB if they had had five or fewer nodes
examined, 3,240 patients remained with a median age of
60 years (range 24–96 years). Of these patients, 1767 had
micrometastatic disease in the SLN and an ipsilateral
regional event was seen in 0.1 %.
Bilimoria et al.10 identified 97,314 patients in the United
States National Cancer Data Base with clinically node-
negative breast cancer who had had a positive sentinel
node. Of these, 20.8 % had undergone a SLNB without a
cALND. Only patients diagnosed between 1998–2000 with
a follow-up reported between 2004 and 2006 were used in
the outcome analysis; 1,988 (9.8 %) had only undergone
SLNB. The median age was 58 years (range 49–69 years),
median follow-up was 64 months. Axillary recurrences
were seen in 0.6 % of the 530 patients with microscopic
nodal metastases.
The 25 other studies reported on smaller cohorts in
which the ARR varied between 0 and 3.7 %. The median
age was 58 years (range 53–67 years), most patients had
undergone BCT (44–100 %) and had received some form
of adjuvant systemic therapy (36–100 %). Nine studies
reported on radiotherapy of the axilla in 2–63 % of
patients.14,16,19,25–27,29,35,39
ARR After Macrometastases are Found in the Sentinel
Node
Table 2 shows 16 studies that described patients with
macrometastatic disease in the SLN in whom a cALND
had not been performed. A total of 3,268 patients were
identified, with a median follow-up of 43 months (range
1–142 months). Twenty-four axillary recurrences were
observed (0.7 %). In this group the median age was
58 years (range 53–64 years). The national database study
by Yi et al.22 showed an ARR of 0.1 % in 1,473 patients
with macrometastatic disease; Bilimoria et al.10 found an
ARR of 1.2 %. The studies that reported on smaller cohorts
showed an ARR between 0 and 7.1 %. The latter was
observed in a study with only 14 patients. In case of
macrometastatic disease in the sentinel node, 6 studies
reported that patients had been treated with axillary
radiotherapy in 2–63 % of the patients.14,16,19,29,35,40 In the
majority of patients who developed an axillary recurrence
(n = 24) details regarding the type of surgery of the pri-
mary tumor were lacking. Three of the patients in this
group were treated with BCT. Detailed information
regarding adjuvant radiotherapy was also lacking. Of the
24 patients with an axillary recurrence, 3 patients received
radiotherapy. In the other patients, only percentages of
radiotherapy in the total group of patients were given
(21 % up to 72 %).9,10,22,24
Table 3 shows four studies that reported SLNB posi-
tivity, but which did not describe the exact sentinel node
status. A total of 409 patients with a median follow-up of
55 months were identified. The ARR varied between 0 and
2.1 %, and a total of 7 axillary recurrences had been noted.
One study included patients receiving axillary radiother-
apy; however, this applied to only 15 % of the patients.21
DISCUSSION
Recent studies have questioned the need for a cALND in
patients with a positive SLNB because the ARR is

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Recurrence After a Positive SLNB 4143
relatively low if cALND has not been performed. In daily
practice, a shift toward omitting the cALND in these
patients is taking place, especially in those patients with
micrometastatic disease. Results from two large database
studies in the US demonstrate that already 16.4–20.8 % of
the patients with a positive sentinel node did not undergo
axillary treatment.10,22 The present review demonstrates
low ARRs in studies which included at least 100 patients
for patients who did not undergo a cALND although they
had a tumor-positive SLNB.9,10,16,18,22 The rates varied
between 0 and 0.9 % for micrometastatic disease and 0.2 to
1.2 % for macrometastatic disease. These rates are com-
parable to those seen in patients with a positive SLNB in
which a cALND had been performed (recurrence rates
between 0.2 and 1.0 %).9,10 The rates found are also of the
same magnitude as those for patients with a negative SLNB
























Yi et al.22 2010 1,473 61 69 NM 79b NR NM 50a 3 (0.2 %)
Giuliano et al.9 2010 199 54 70 36 100 60/48b NM 76 2 (0.9 %)b
Takei et al.19 2010 32 55 30 78 92b 19/77b 52b 58a 0
Yegiyants et al.24 2010 14 57 66 43 100 92/76b 0 79 (6–142) 1 (7.1 %)
Bilimoria et al.10 2009 1,458 58a 63a NM 81b 71/74b NM 64 (60–72) 18 (1.2 %)
Zakaria et al.29 2008 17 62 62 29 60b 53/87b 19b 30 (3–66) 0
Hwang et al.16 2007 39 56 72 22 69b 56/27b 58b 30 (1–62) 0
Schulze et al.31 2006 1 64c 100a 0 74b 3/68a NM 49 (?/NM 17)a 0
Haid et al.32 2006 2 59a 77a NM 87b 32/93a NM 47 (7–90) 0
Swenson et al.33 2005 4 59a 82a NM 75b 42/58a NM 33 (2–73) 0
Schrenk et al.34 2005 4 59a 61a NM 29b NR 0 48 0
Fan et al.35 2005 11 53a 71 28 NM NR 63b 31 (6–76) 0
Chagpar et al.36 2005 1 57a 89a 2 86b 33b NM 40 (1–54) 0
Carlo et al.37 2005 2 57a 84a NM 92a 100 NM 60a 0
Guenther et al.14 2003 7 62 67 NM NM 100 2b 32 (4–61) 0
Fant et al.40 2003 4 NM 81 NM NM 100 3b 30 (21–48) 0
SLNB sentinel lymph node biopsy, LVI lymphovascular invasion, RT radiotherapy, NR not reported (patients received systemic therapy, but the
exact percentage was not reported), NM not mentioned in the article, SN sentinel node
SN status macrometastatic disease ([2.0 mm)
a Total group (not specified separately for SN-positive patients)
b Not specified separately for SN status
c For all SN, including both SN negative and positive
























Giuliano et al.9 2010 66 54b 70 36 100 60/48b NM 76 1 (0.9 %)b
Geertsema et al.43 2010 39 60a 64a NM NM NM NM 40b 0
Park et al.21 2007 287 59 78 22 68 NR 15 23 (6–87) 6 (2.1 %)
Calhoun et al.42 2005 17 64 65 NM NM 88 NM 81a 0
SLNB sentinel lymph node biopsy, LVI lymphovascular invasion, RT radiotherapy, NR not reported (patients received systemic therapy, but the
exact percentage was not reported), NM not mentioned in the article, SN sentinel node
SN status not specified
a Total group (not specified separately for SN-positive patients)
b Not specified separately for SN status
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(without cALND) for whom the ARR ranged from 0.3 to
1.4 %.11,44
In this review we included the preliminary results from
the ACOSOG Z0011 trial. This is the only prospective trial
in which patients with sentinel node metastases were ran-
domized to undergo axillary lymph node dissection after
SLNB versus SLNB without specific axillary treatment.9
All these patients were treated with BCT and tangential
field whole breast irradiation. In addition, the majority of
the patients (97 %) in that study received adjuvant sys-
temic treatment. At a median follow-up of 6.3 years
(interquartile range 5.2–7.7), no significant difference was
seen in the ARR between the two groups (0.5 % in the
cALND group and 0.9 % in the group without cALND).
Moreover, overall survival was not different in both study
arms.45 Unfortunately, the trial was underpowered and
closed early because accrual was low and the ARR was
lower than expected in both arms.9,45
In addition to the low chance of recurrence shown by the
ARR, there are other arguments to eliminate a cALND for
selected patients. First of all, in the current guidelines adju-
vant systemic therapy is advised on the basis of tumor and
patient characteristics and axillary lymph node involvement.
Treatment recommendations are rarely altered by the addi-
tional information gained by the cALND results. Geertsema
et al.43 reported additional tumor positive axillary lymph
nodes in 16 % of the patients undergoing a cALND after a
negative frozen section. None of those patients would have
received additional systemic therapy on the basis of the
cALND findings. The AMAROS trial compared cALND
with axillary radiotherapy in positive sentinel node patients.
It also demonstrated that information obtained from cALND
rarely altered treatment recommendations made before the
cALND.4,6 Although patients with four or more positive
lymph nodes are supposed to receive adjuvant radiotherapy
on the axilla and supraclavicular region, that was only nec-
essary in 12 % of the patients in the trial.6,46 Most probably
the majority of patients with four or more positive lymph
nodes were preoperatively identified by palpation or ultra-
sound as being node positive and did not undergo SLNB as
such patients routinely undergo an axillary dissection at the
same time as treatment for the primary tumor.
Secondly, only in 10–20 % of patients with ITCs and
micrometastases and around 40 % of patients with ma-
crometastases does the cALND contains additional lymph
node metastases.6,47 Several nomograms have been devel-
oped to predict the chance of additional lymph node
metastases; however, each has limitations.48,49 Because in
the general population the majority of additional lymph
nodes are negative, performing a cALND would have no
therapeutic value or additional staging effects.
Thirdly, the effect of additional systemic therapy in
patients with node positive disease is an important issue. A
few decades ago Canabes et al.50 had reported that the
ARR in patients with tumors smaller than 3 cm was only
2 % if the axilla had not been treated. That study compared
axillary dissection to no axillary dissection. However, that
occurred in an era in which only a minority of the patients
were treated with adjuvant systemic therapy. Now that
modern systemic therapy is given in almost all patients
with a positive SLNB, the recurrence rate now that can be
expected will most probably be lower. The MIRROR trial
studied the effects of systemic therapy in patients with
ITCs or micrometastases regardless of axillary treatment; it
demonstrated an improvement of disease-free survival in
patients who had received adjuvant systemic therapy.51 In
neo-adjuvant chemotherapy protocols, not only is the size
of the tumor substantially reduced but also the size of
lymph node metastases.52 Pathological complete response
by the primary tumor has been demonstrated to be highly
predictive of pathological complete response in the axillary
nodes.53 Charfare et al.54, Vlastos et al.55 and Kuerer
et al.56 reported a pathologically complete response in
3–34 % of the patients. Thus, patients with a positive
lymph node status at initial evaluation, can be considered
to have a negative axillary nodal status as a result of neo-
adjuvant chemotherapy.54–56 This effect might also be of
importance in adjuvant chemotherapy protocols. Therefore,
potentially positive lymph nodes in the axilla could be
sterilized by chemotherapy, which would then reduce the
theoretical ARR.
Fourthly, not only systemic therapy but also adjuvant
radiotherapy can be regarded as a treatment modality for
any remaining axillary lymph node metastases. Radio-
therapy to the breast as part of BCT includes the lowest
portion of the axilla. In several studies it has been objec-
tified that the clip marking the SLN fell within the standard
tangential fields of the whole breast radiotherapy in
78–94 % of the patients.57,58 Veronesi et al.59 described
that radiotherapy to the breast is one of the possible
explanations for the lower than expected numbers of axil-
lary metastases in the no axillary radiotherapy arm of their
randomized trial to assess the role of axillary radiotherapy.
A recently published systematic review demonstrated that
patients with a node negative SLN who underwent radio-
therapy had a significantly lower rate of axillary
recurrences as compared to patients who had not been not
treated with postoperative radiotherapy of the breast.60
A limitation of this review is the fact that all but one of
the reviewed studies were retrospectively analyzed. It is
therefore difficult to control for treatment bias and selec-
tion bias. In some studies patients were more likely to be
older and have more favorable tumors characteristics such
as smaller size, low tumor grade and less lymphovascular
infiltration than in the general breast cancer population.
This is shown in Table 4 by the trend for smaller tumor
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size, more BCT and micrometastases in patients who has
been treated with only SLNB. Unfortunately, details on the
type of surgery or adjuvant radiotherapy for those patients
who developed an axillary recurrence was not presented in
the majority of the different studies. Axillary recurrences
were reported in 6 patients after BCT and 2 after mastec-
tomy, whereas in 28 patients it was not described in detail.
Also, the results extracted from the two American database
studies dominated the results of this review because of the
greater number of patients in comparison with the other 28
studies. In those database studies the selection bias is
substantial because patients were selected to undergo only
SLNB if they were more likely to have a favorable prog-
nosis. Also, these cancer registries may underreport
axillary recurrences because the definition ‘‘ipsilateral
regional events’’ is used instead of ‘‘axillary recurrence.’’
Although the other studies do use the exact definition,
underreporting might still occur in all studies because of
their retrospective nature.
The mean follow-up in the studies in this review ranged
between 1 and 142 months, which is relatively short for
drawing definite conclusions about axillary recurrence.
However, studies with long-term follow-up have shown
that the majority of locoregional recurrences, including
TABLE 4 Patients, tumor and
treatment characteristics in
studies with [100 patients who
underwent SLNB only for
positive breast cancer,
compared with patients who
underwent ALND
SLNB sentinel lymph node
biopsy, ALND axillary lymph
node dissection, LN lymph
node, NM not mentioned in the
article, SN sentinel node,
x = no comparison with a
group patients treated with
ALND is made
a Studies are as follows: Yi
et al.22, Giuliano et al.9, Takei
et al.19 (total group, not
specified separately for SN-
positive patients), Bilimoria
et al.10, Hwang et al.16 (total
group, not specified separately
for SN-positive patients), and
Park et al.21 (in ALND
95.7 % [ 10 nodes excised, in
SLNB 85 % 1–9 nodes excised)
b After breast-conserving
surgery
Favorable characteristic Studya ALND SLNB only
Tumor size \2 cm (%) Yi et al. 50.4 68.6
Giuliano et al. 67.9 70.6
Takei et al. x 29.5
Bilimoria et al. 49.1 62.9
Hwang et al. x 72.4
Park et al. 62 78
Radiotherapy (%) Yi et al. 53.6 59.9
Giuliano et al. NM NM
Takei et al. x 84.8
Bilimoria et al. 72.1b 72.1b
Hwang et al. x 58.2
Park et al. NM 15
Median age (y) Yi et al. 55 60
Giuliano et al. 56 54
Takei et al. x 55
Bilimoria et al. 56 58
Hwang et al. x 56
Park et al. 52 59
Breast-conserving surgery (%) Yi et al. 53.9 78.7
Giuliano et al. 100 100
Takei et al. x 92.4
Bilimoria et al. 49.6 81.4
Hwang et al. x 68.9
Park et al. 55 68
Micrometastases (%) Yi et al. 17.2 54.5
Giuliano et al. 37.5 44.8
Takei et al. x 56.8
Bilimoria et al. 8.5 18.2
Hwang et al. x 45.9
Park et al. NM NM
No. of LNs removed, median (range) Yi et al. 15 (9–64) 2 (1–5)
Giuliano et al. 17 2
Takei et al. x 3 (1–11)
Bilimoria et al. 15 (12–20) 2 (1–3)
Hwang et al. x 3 (1–14)
Park et al. [10 NM (1–9)
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axillary relapses, occur within five years of the initial
treatment and most axillary recurrences (approximately
90 %) are evident within the first 2 or 3 years after surgery.
This compares well to the median follow-up for the present
study.61,62
Heterogeneity among the included studies was sub-
stantial and is a major drawback of this review. Although
BCT was performed in the majority of patients for all
reviewed studies, the results in each individual study were
not given separately for BCT versus mastectomy. With
regard to adjuvant treatment, most of the studies reported
that adjuvant treatment was given according to the national
guidelines, but the adjuvant treatment was not specified for
those patients with a recurrence. Radiotherapy on the axilla
was also given in 10 of these studies but a substantial
number of patients in each study did not receive that
therapy. This is an important issue because the MA.20
preliminary report demonstrated a reduction in locore-
gional recurrence when the axilla has been irradiated.63
This makes it difficult to form definite conclusions about
the influence of adjuvant systemic therapy and radiother-
apy on the recurrence rate. The absence of the distinction
between micrometastases and ITCs in some of the studies
is also a drawback because patients with ITCs in the SLNB
are nowadays classified as ‘‘node-negative patients,’’ not
requiring a cALND. Recently Jakub et al.64 suggested that
not the number of positive SLN, but the number of positive
non-SLNs is important for prognosis. Details about this
issue of additional non-SLN positivity are lacking in the
reviewed studies.
Lastly, the definition and surgical technique of the
SLNB itself is a limitation. In daily routine most patients
have one or two SLNs, but in the six studies with 100 or
more patients in this review mean number of biopsied
nodes is 2–11 nodes. In the two large American databases,
before analysis with lymph node count threshold (five or
fewer nodes examined) 4–16 nodes and 1–44 nodes were
included as SLNB patients, which should probably be
considered as complete axillary lymph node dissections.
Overall survival was not subject of this review, although
it is clinically relevant to investigate whether omission of
cALND affects survival. Yi et al.22 stated that compared
with SLNB alone, cALND does not seem to be associated
with improved survival in patients with micrometastasis in
the SLNB. Bilimoria et al.10 described that, in case of
micrometastases, a cALND does not appear to improve the
overall outcome, as there were no significant differences in
survival or in axillary recurrences. In case of macrometa-
static disease, there was a nonsignificant trend toward
better outcomes in axillary recurrences and survival after
cALND, but only after analysis was adjusted for clinico-
pathologic differences.10 In the ACOSOG Z0011 trial,
Giuliano et al.65 observed no differences in overall survival
between the cALND arm and the arm in which cALND
was not performed. Long-term results and the impact of the
omission of axillary lymph node dissection on survival are
awaited.
In conclusion, this review shows that the ARR is low in
patients with a positive SLNB, even if a cALND is not
performed. Recent efforts to develop nomograms in order
to predict which patients should undergo a cALND, fails to
identify patients who really benefit of this procedure. On
the contrary, avoiding a cALND seems to be safe in the
majority of SLNB-positive patients, especially in case of
ITCs or micrometastatic disease. In patients who meet the
Z0011 trial criteria and undergo adjuvant radiotherapy and
chemotherapy, cALND has little to no effect on local
recurrence and survival. However, large (prospective ran-
domized) studies are lacking for patients with a potentially
higher risk for regional recurrences such as multiple ma-
crometastases in the SLN, patients with larger primaries,
patients who underwent neoadjuvant chemotherapy or
patients undergoing mastectomy or BCT without radio-
therapy. Such randomized trials or large clinical cohort
studies are necessary to investigate the long-term effects on
axillary recurrences and survival of omitting cALND in
high risk patients.66,67 In the future, cALND will probably
be used as an effective treatment procedure rather than a
procedure to prevent axillary recurrence.68
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